Rociletinib Hydrobromide
N/A
Report date: 2022/10/25 13:05:15
NME
Base Information
Drug NameRociletinib Hydrobromide
Drug Alias Name +[7]
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory +[14]
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCelgene Corp
China Registration ClassN/A
Develop Information
Active CompaniesN/A
Inactive CompaniesClovis Oncology IncWashington University School Of Medicine
Active IndicationsN/A
Inactive Indications